For research use only. Not for therapeutic Use.
Fazpilodemab (BFKB8488A) is a humanized, agonistic, bispecific antibody targeting fibroblast growth factor receptor 1c (FGFR1c) and Klothoβ. Fazpilodemab can be used for the research of type 2 diabetes mellitus (T2DM) or nonalcoholic fatty liver disease (NAFLD)[1].
| Catalog Number | I042106 |
| CAS Number | 2517935-02-1 |
| Purity | ≥95% |
| Reference | [1]. Wong C, et al. Fibroblast growth factor receptor 1/Klothoβ agonist BFKB8488A improves lipids and liver health markers in patients with diabetes or NAFLD: A phase 1b randomized trial. Hepatology. 2022 Aug 22. |
